Search CRNX
Crinetics Pharmaceuticals, Inc.
Nasdaq · CIK 1658247
Last close84.95
Daily changen/a
10 Years gain+246.59%
Dividends TTM0
Dividend yieldn/a
Fundamental Analysis
CRNX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
59.7Momentum
100.0Acceleration
100.0Confidence
65.0Annual Revenue10
Quarterly Revenue36
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality15.7 / 25
Capital Efficiency4.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 23923.1744 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 13.381%.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM2,544.71%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin99.04%OK
Operating Margin-1,470.68%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-1,201.29%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y13.38%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $7.70M | $6.62M | -$516.77M | -$377.92M | -$383.68M | 86.02% | -6,714.77% | -4,985.5% | n/a | 94.06M |
| 2025 FY Dec 31, 2024 | $1.04M | $1.04M | -$338.85M | -$230.19M | -$234.04M | 100% | -32,613.47% | -22,525.31% | n/a | 80.78M |
| 2025 FY Dec 31, 2023 | $4.01M | $4.01M | -$222.61M | -$168.60M | -$173.29M | 100% | -5,547.17% | -4,318.12% | n/a | 58.07M |
| 2024 FY Dec 31, 2022 | n/a | $4.74M | -$167.88M | -$115.21M | -$116.86M | n/a | n/a | n/a | n/a | 51.98M |
| 2022 FY Dec 31, 2022 | $0.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $37.03M | sum latest 4 fiscal quarters Revenue | OK | 0001658247-26-000053, 0001658247-25-000019 |
| Revenue Growth TTM | 2,544.71% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001658247-26-000053, 0001658247-25-000019 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001658247-26-000012 |
| Revenue CAGR 5Y | 155.27% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001658247-26-000012 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001658247-26-000012 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001658247-26-000053, 0001658247-25-000019 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 99.04% | Gross Profit / Revenue | OK | 0001658247-26-000053, 0001658247-25-000019 |
| Operating Margin | -1,470.68% | Operating Income / Revenue | OK | 0001658247-26-000053, 0001658247-25-000019 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001658247-26-000053 |
| Current Ratio | 15.57x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.35 | Revenue / Diluted Shares | OK | 0001658247-26-000053, 0001658247-25-000019 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001658247-26-000012 |